News
NICE (UK) terminated appraisal for Skyclarys (omaveloxolone) for treating Friedreich’s ataxia in people 16 years and over - Biogen
NICE (UK): NICE is unable to make a recommendation on omaveloxolone (Skyclarys) for treating Friedreich’s ataxia in people 16 years and over. This is because Biogen withdrew its evidence submission. NICE will review this decision if Biogen decides to make a new submission.
Condition: Friedreichs Ataxia
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins